Antibody developer Genmab has made a play to boost its expertise in the scalding hot area of antibody-drug conjugates (ADCs), agreeing a $1.8 billion deal to acquire Profo
AbbVie’s CD20xCD3 bispecific antibody Tepkinly has been recommended by NICE for NHS use as a treatment for relapsed or refractory diffuse large B-cell lymphoma (DLBCL), an
Sanofi’s anti-CD38 antibody Sarclisa has struggled to make headway against Genmab and Johnson & Johnson’s rival Darzalex since it was first approved for multiple myelo
A year after GSK pulled its BCMA-targeting antibody-drug conjugate (ADC) Blenrep from the US market as a later-line therapy for multiple myeloma, there are signs that the
Seagen and Genmab's antibody-drug conjugate Tivdak has been shown to improve overall survival when used as a second-line monotherapy for recurrent or metastatic cervical c
Johnson & Johnson has agreed a $850 million deal to acquire Proteologix that will give it a pair of early-stage bispecific antibodies with immunology applications, inc
It’s 2024, and in most clinical trials, data is still being moved from the EHR to the EDC manually – with employees reading data from one screen and typing it onto another.